
    
      This is a multicenter, randomized, double-blind, placebo-controlled study of IC14, an
      antibody to CD14, in reducing the severity of respiratory disease in hospitalized Coronavirus
      Disease 2019 (COVID-19) patients.

      Participants will be randomized to IC14 or matching placebo and followed for 60 days after
      randomization. The study drug will be administered daily on Days 1-4 by intravenous infusion.
      All participants will receive standard of care antiviral therapy with remdesivir.
    
  